Form 4: Arrowhead CMO Granted 75,000 RSUs

Arrowhead Pharmaceuticals' Chief Medical Officer, James C. Hamilton, was granted 75,000 restricted stock units vesting over four years.

Summary

• James C. Hamilton, Chief Medical Officer of Arrowhead Pharmaceuticals, Inc. (ARWR), acquired 75,000 shares of common stock.
• These shares represent restricted stock units (RSUs) granted on January 6, 2026, with a transaction price of $0.
• The RSUs will vest in four equal annual installments.
• Following this transaction, Mr. Hamilton beneficially owns 246,958 shares of common stock, which includes previously reported RSUs still subject to vesting conditions.
• The transaction was made pursuant to a Rule 10b5-1 plan.

Sentiment

Score: 7

Explanation: A routine executive equity grant, generally positive for retention and alignment, but not a major market-moving event.

Positives

• Grant of 75,000 restricted stock units to the Chief Medical Officer, aligning executive incentives with shareholder interests.
• The transaction was executed under a Rule 10b5-1 plan, indicating a pre-arranged trading plan designed to avoid insider trading allegations.

Negatives

• NA

Risks

• NA

Future Outlook

The restricted stock units will vest in four equal annual installments, indicating a long-term incentive and retention strategy for the Chief Medical Officer.

Management Comments

• NA

Industry Context

The grant of restricted stock units to a key executive like the Chief Medical Officer is a common practice in the biotechnology and pharmaceutical industry to attract, retain, and incentivize top talent, aligning their long-term interests with company performance and shareholder value.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a component of executive compensation is a widely adopted practice across the pharmaceutical and biotech sectors, comparable to compensation structures at companies like Moderna, Pfizer, or Johnson & Johnson, which frequently utilize equity grants to incentivize long-term performance and retention.

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Aligns the Chief Medical Officer's long-term financial interests with the company's performance, potentially fostering greater commitment to value creation.
• Employees (CMO): Provides a significant long-term incentive, enhancing retention and motivation for a key executive.

Next Steps

• The restricted stock units will vest in four equal annual installments, commencing from the grant date.

Key Dates

Recommendation

This Form 4 reports a routine grant of restricted stock units to a key executive, which is a standard compensation practice aimed at executive retention and alignment of interests. While positive for corporate governance and long-term executive commitment, it does not present new information that would fundamentally alter the investment thesis or warrant a change in an existing 'hold' recommendation. It's an expected operational event rather than a catalyst for significant price movement.

Keywords

Arrowhead Pharmaceuticals, ARWR, Form 4, RSU, Restricted Stock Units, Insider Transaction, Chief Medical Officer, James C. Hamilton, Equity Grant, Executive Compensation